NCT01306630 - A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Advanced Solid TumorsLocally Advanced or Metastatic Breast or Colorectal Cancer

Interventions

DRUG

tivozanib (AV-951) and capecitabine (Xeloda®)

Tivozanib 1.0 mg or 1.5 mg oral once daily for 2 weeks followed by 1 week off. Capecitabine 825 mg/m2, 1000 mg/m2, or 1250 mg/m2, oral twice daily for 2 weeks followed by 1 week off. 1 cycle= 3 weeks. Cycles will be repeated in the absence of disease progression or unacceptable toxicity.

Trial Locations (3)

33908

Fort Myers

37203

Nashville

85258

Scottsdale